Literature DB >> 6511338

Clofibrate-induced muscular syndrome. Case report with ultrastructural findings and review of the literature.

D Rimon, R Ludatscher, L Cohen.   

Abstract

A 70-year-old man with chronic renal failure was treated with clofibrate, 2.0 g daily for 6 days, and subsequently developed clofibrate-induced muscular syndrome (CMS), i.e., myalgia with severe muscle weakness and tenderness. Elevated muscular enzyme activities were found upon examination of his blood. Electron microscopic studies revealed atrophy of some muscle fibers and massive degenerative changes. The atrophic fibers were associated with damaged neuromuscular junctions. A literature survey of 44 cases with CMS is included.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6511338

Source DB:  PubMed          Journal:  Isr J Med Sci        ISSN: 0021-2180


  5 in total

Review 1.  Clinical features, pathogenesis and management of drug-induced rhabdomyolysis.

Authors:  C Köppel
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Mar-Apr

2.  Effect of clofibrate in jaundiced term neonates.

Authors:  S Wazir; R R Angiti; P Kumar
Journal:  Indian J Pediatr       Date:  2006-02       Impact factor: 1.967

Review 3.  HMG-CoA reductase inhibitors and myotoxicity.

Authors:  M Ucar; T Mjörndal; R Dahlqvist
Journal:  Drug Saf       Date:  2000-06       Impact factor: 5.606

Review 4.  How well tolerated are lipid-lowering drugs?

Authors:  B Tomlinson; P Chan; W Lan
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

5.  Oral nanoparticulate atorvastatin calcium is more efficient and safe in comparison to Lipicure in treating hyperlipidemia.

Authors:  A K Meena; D Venkat Ratnam; G Chandraiah; D D Ankola; P Rama Rao; M N V Ravi Kumar
Journal:  Lipids       Date:  2008-01-10       Impact factor: 1.880

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.